This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Clinical Oncology Next-generation Sequencing Market

Market Insights on Clinical Oncology Next-generation Sequencing covering sales outlook, demand forecast & up-to-date key trends

Clinical Oncology Next-Generation Sequencing Market by Component (Sequencing Platforms, Sequencing Products, Kits and Reagents and Services), Technology (Ion Semiconductor Sequencing, Pyro-Sequencing & Region - Forecast 2022 - 2029

Clinical Oncology Next-Generation Sequencing (NGS) Market Outlook – 2022-2029

[194 Pages Report] The global Clinical Oncology Next-Generation Sequencing Market is estimated to be worth around US$ 449.4 Mn in 2022. With rising adoption of next generation sequencing (NGS) in clinical oncology for advance personalized treatment of cancer, the overall market is projected to expand at a prolific CAGR of 16.3% between 2022 and 2029, reaching a valuation of US$ 1.14 Bn by 2029.

Attribute

Details

Clinical Oncology Next-Generation Sequencing Market Estimated Size in 2022

US$ 449.4 Mn

Clinical Oncology Next-Generation Sequencing Market Projected Size in 2029

US$ 1.14 Bn

Clinical Oncology Next-Generation Sequencing Market Historical CAGR (2014-2021)

14.4%

Clinical Oncology Next-Generation Sequencing Market Value-Based CAGR (2022-2029)

16.3%

Rising global burden of cancer has encouraged innovations in the diagnostic and treatment approaches. Next generation sequencing has been gaining traction since the last few years. Currently clinical oncology next generation sequencing market forms around 3.8% share of the global next generation sequencing market.

Kits and reagents will continue to remain the most adopted products in clinical oncology, accounting for a major share of 59.8% in 2022. They are being widely adopted across multiple applications.

Customize this Report

Let us know your requirement to get
100% FREE customization

How The Market Progressed Till June 2022?

Particulars

Details

H1, 2021

17.33%

H1, 2022 Projected

16.28%

H1, 2022 Outlook

16.18%

BPS Change - H1, 2022 (O) – H1, 2022 (P)

(-) 10 ↓

BPS Change – H1, 2022 (O) – H1, 2021

(-) 115 ↓

According to Future Market Insights' analysis, the global clinical oncology next-generation sequencing market expects to drop by 115 Basis Point Share (BPS) in H1-2022 as compared to H1- 2021. Whereas in comparison to H1-2022 Projected value, the market during H1-2022 outlook period will show a dip of 10 BPS.

The dip in the BPS values could be associated with the observed critical influence of existing proprietary variant databases, and inconsistent standard coverage for next-gen sequencing owed to inconsistent payer polices.

The key developments in the market include the development of technologies in cancer diagnosis, management and treatment, such as the Infinium Assay, CRISPR, AI, telehealth, cryo-electron microscopy, and robotic surgery.

Consequently, through these developments, the market for clinical oncology next-generation sequencing is expected to observe a positive growth outlook during the forecasted years.

The market is subject to changes associated with the regulatory dynamics, reimbursement policies, and capital expenditure, in accordance to the macro and industry factors.

2014-2021 Clinical Oncology Next-Generation Sequencing Market Outlook Compared to 2022-2029 Forecast

The global clinical oncology next-generation sequencing market is set to register a CAGR of 16.3% between 2022 and 2029 in comparison to 14.4% CAGR registered from 2014 to 2021.

Rising popularity of personalized medicine in clinical oncology, increasing prevalence of cancer, growing need for early diagnosis and treatment of cancer and continued advancements in cancer research are some of the factors driving the global clinical oncology next generation sequencing market.

Next-generation sequencing has emerged as an ideal technique for the diagnosis and treatment of various diseases. It has revolutionized the genomic research due to its ultra-high throughput, scalability, and speed. The technology is used to determine the order of nucleotides in entire genomes or targeted regions of RNA or DNA.

With continuous advances in sequencing technology, NGS has gained wider popularity across various applications. It is being increasingly adopted in clinical oncology for molecular diagnostics and advance personalized treatment of cancer.

NGC can effectively help in identification of novel and rare cancer mutations, detection of familial cancer mutations and thus enable clinicians to make better treatment decisions for cancer patients. Thanks to its ability to identify many genes simultaneously, it can save both time and money.

Rising prevalence of cancer is a major force driving the global clinical oncology next generation sequencing market. According to the International Agency for Research on Cancer (IARC) of World Health Organization (WHO), Cancer was the leading cause of death worldwide, accounting for around 10 million deaths in 2020. Furthermore, around 19.3 million new cases were reported worldwide. In order to tackle this global burden and reduce the mortality rate, new innovative approaches such as next generation sequencing are being employed. This is in turn accelerating the growth of clinical oncology next generation market.

Reducing cost of NGS platforms is another factor boosting the growth of the market. Clinical oncology next-generation sequencing techniques offer a high percentage of reads and cost-effectiveness per read. Leading players are introducing new sequencing techniques with low costs.

Similarly, rising adoption of next generation sequencing for liquid biopsy will further expand the global clinical oncology next generation sequencing market over the forecast period.

Spurred by the aforementioned factors, the market volume for Clinical oncology next-generation sequencing market is set to expand 2.6X through 2029.

How Will Rise in Government and Private Funding Affect Clinical Oncology Next Generation Sequencing Market?

Rapidly rising cases of cancer has become a serious concern around the world. The disease not only results in loss of lives but also impacts the economic condition of countries. As a result, government and various other healthcare organizations are taking initiatives to counter the global burden of cancer.

Large funds are being allocated to research institutes to search for effective treatments and medicines. New projects are being initiated to make complete analysis of human genome.

For instance, in July 2021, the National Cancer Center Japan launched the fourth-stage study of Japan's first Cancer Genome Screening Project for Individualized Medicine in advanced solid tumors.

In December 2021, over US$1.2 million was awarded to fund 20 breast cancer research projects across Alabama.

Similarly, the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI), launched the Cancer Genome Atlas (TCGA) project together. The project aimed to fully explore the entire spectrum of genomic changes involved in human cancer.

As next generation sequencing is the most advanced technology available, researchers and clinicians are adopting it for these purposes. This is fueling the growth of clinical oncology next generation sequencing market and the trend is likely to continue in the future.

Launch of these various projects supported by increasing government and private funding is anticipated to boost the growth of clinical oncology next generation sequencing market over the forecast period.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Country-wise Insights

What is Demand for Clinical Oncology Next Generation Sequencing Surging in the U.S?

“Increasing Investments in Cancer Research Augmenting Demand in U.S,”

The U.S. will remain one of the primary markets for clinical oncology next generation sequencing. Rising investments in medical research, presence of leading healthcare institutions, increase in cancer cases and growing adoption of NGS in diagnostic and research purposes are some of the factors driving the U.S. clinical oncology next generation sequencing market.

Over the last few years, there has been a rapid increase in the cancer cases, which has prompted government and other healthcare organizations to take various measures. According to the American Cancer Society’s report, an estimated 1,898,160 new cancer cases and about 608,570 cancer deaths are projected to occur in the United States during 2021. The rising cases of cancer and consequent demand for advanced treatment solutions are anticipated to provide impetus to the clinical oncology next generation sequencing market in the country.

Similarly growing popularity of personalized medicine for the effective treatment of cancer is creating huge scope for next generation sequencing technology. These new innovative technologies are helping researchers to design more effective treatments.

Various efforts are being taken by the U.S. and other regulatory bodies to increase cancer screening diagnosis as well to develop effective treatment approaches. Research funding from organizations like the National Institutes of Health (NIH) and the National Cancer Institute (NCI), is creating huge scope for the growth of clinical oncology next generation sequencing market in the country.

Moreover, heavy presence of leading market players such as Illumina, Inc. and Thermo Fisher Scientific is positively impacting the market growth.

What is the U.K Clinical Oncology Next-Generation Sequencing Market Demand Outlook?

“Next Generation Sequencing Remains Highly Sought After for Predictive Genetic Testing”

As per FMI, the U.K. is clinical oncology next generation sequencing market is slated to grow at a stellar growth during the forecast period. Growth in the region is attributable to rising prevalence of cancer, growing demand for advanced technologies such as NGS and increasing investments in cancer research.

According to the Cancer Research UK, there are around 375,000 new cases of cancer ever year in the U.K. Rise in the cases of cancer at this alarming rate has brought new diagnostic and treatment technologies into spotlight.

Growing awareness about the benefits of next generation sequencing is fueling its adoption. Clinicians and other healthcare experts are increasingly employing next generation sequencing platforms to make proper assessment of the cancer and thus initiate better treatment approaches.

Predictive genetic testing through next generation sequencing is gaining traction across the country. It is being used to look for inherited gene mutations that might put a person at higher risk of getting certain kinds of cancer.

In addition to this, increase in the number of diagnostic laboratories, clinical research organizations and other cancer research institutions is supporting the growth of clinical oncology next generation sequencing market in the country.

How Will Growth Unfold in China Clinical Oncology NGS Market?

“Rising Cancer Burden Driving Demand in China”

With its highly sophisticated healthcare infrastructure, China has garnered a lot of attraction as an ideal destination for cancer treatment. Annually, thousands of cancer patients are treated in hospitals and other cancer clinics across the country.

Rapidly growing population, increasing penetration of new medical technologies, easy availability of advanced products at low costs and favorable government support are some of the factors driving the clinical oncology next generation sequencing market in China.

According to the International Agency for Research on Cancer, total new cancer cases in China surged to 4568754 in 2020. The government in the country spends millions of dollars on cancer researches.

Leading market players in the country are introducing novel products at affordable prices. They are collaborating with healthcare and research institutes to increase their sales.

Category-wise Insights

Which is the Most Commonly Adopted Component in the Global Clinical Oncology Next Generation Sequencing Market?

“Easy and Convenient Nature of Clinical Oncology NGS Kits and Reagents Fuelling Their Adoption”

Based on product, clinical oncology next generation sequencing market is segmented into sequencing platforms, sequencing products, kits and reagents and services. Among these, kits and reagents segment dominate the clinical oncology next generation sequencing market, accounting for 59.8% share in 2022.

Kits and reagents are the most commonly used products for next generation sequencing applications due to their convenient and affordable nature. Rising adoption of kits and reagents for cancer research and advanced precision medicines will boost their sales during the forecast period.

Which is the Preferred Technology in the Clinical Oncology Next Generation Sequencing Market?

“End Users Prefer Sequencing by Synthesis Technology for Better Genomic Sequencing”

Based on the technology, the clinical oncology next-generation sequencing market has been segmented into ion semiconductor sequencing, pyro sequencing, synthesis sequencing, real time sequencing, ligation sequencing, reversible dye termination sequencing and nano-pore sequencing.

Among these, synthesis sequencing or sequencing by synthesis (SBS) segment is expected to hold a significant share in the clinical oncology next-generation sequencing market at the end of assessment period.

Sequencing by synthesis is a widely adopted next-generation sequencing technology in the world. The technology delivers the highest yield of error free reads and thus enables robust base calling across the genome. It has the ability to fully characterize any genome.

Easy availability of NGS platforms based on SBS technology and increasing adoption of SBS in cancer research, microbial genomics, genetic diseases and various other application will continue to spur the growth of the market.

Which is the Most Lucrative Application for Clinical Oncology Next-Generation Sequencing?

“Rising Need for Effective Treatment Strategies Spurring Targeted Tumor Genome Profiling Segment Growth”

On terms of application, the global clinical oncology next generation sequencing market is segmented into whole tumor genome sequencing, whole tumor exome sequencing, targeted tumor genome profiling, tumor transcriptome sequencing, tumor-normal comparisons and Others.

As per FMI, targeted tumor genome profiling segment is expected to hold a large share of the clinical oncology next-generation treatment market by 2029. Targeted tumor genome profiling is widely used to identify potential therapeutic targets in multiple cancer types.

Using next generation sequencing method for targeted tumor genomic profiling helps the clinicians to provide quick and better treatment option in cancer patients.

Who is the Leading End User of Clinical Oncology Next-Generation Sequencing?

“Increase in Clinical Research Trials Driving Demand in Clinical Research Organization”

On the basis of end user, the clinical oncology next-generation sequencing market has been segmented into hospital laboratories, clinical research organizations, diagnostic laboratories, and others. Among these, clinical research organizations segment is anticipated to account for the largest revenue share through 2029.

Rising adoption of next generation sequencing for research and development of innovative cancer drugs in clinical research organizations is boosting the growth of clinical oncology next generation sequencing market.

Large funds are being allocated to clinical research organizations by both healthcare companies as well as government for research and development of new innovative drugs. Increase in clinical trials across clinical research organizations coupled with growing number of collaborations between clinical research organizations and NGS market players will continue to boost the sales of next generation sequencing products during the forecast period.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Competitive Landscape

Leading players operating in the clinical oncology next-generation sequencing market are using various strategies such as such as partnerships, advanced product launches, collaborations and acquisitions to penetrate lucrative markets and strengthen their global position. For instance,

  • In January 2022, Agendia, Inc., a world leader in precision oncology for breast cancer announced a multi-year partnership with Illumina, to co-develop in diagnostic (IVD) tests for oncology testing.
  • In October 2021, Roche launched the AVENIO tumor tissue CGP kit to expand access to personalized cancer research.
  • In January 2022, Illumina Inc. partnered with Boehringer Ingelheim to accelerate the development of therapy selection and precision medicines for patients with advanced cancer.
  • In August 2020, Ancestry, the global leader in family history and consumer genomics, launched AncestryHealth which is based on next generation sequencing (NGS). AncestryHealth is designed to help people understand their risk for developing certain inheritable health conditions including breast cancer, colon cancer and blood disorders.

Scope of the Report

Attribute

Details

Historical Data Available for

2014-2021

Forecast Period

2022-2029

Market Analysis

Units for Volume and US$ Mn for Value

Key Regions Covered

North America, Latin America, Europe, East Asia, South Asia, Oceania and Middle East and Africa

Key Countries Covered

US, Canada, Mexico, Brazil, Germany, U.K., France, Italy, Spain, Russia, Poland, China, Japan, South Korea, India, ASEAN, Turkey, Saudi Arabia and South Africa

Key Segments Covered

Component, Technology, Application, End User and Region

Key Companies Profiled

  • Illumina, Inc.
  • F. Hoffmann-La Roche Ltd
  • Oxford Nanopore Technologies
  • Agilent Technologies
  • Thermo Fisher Scientific Inc, PerkinElmer, Inc.
  • Becton, Dickinson and Company
  • QIAGEN N.V.
  • Pacific Biosciences of California, Inc.
  • BGI Group
  • Takara Bio, Inc
  • Creative-Biolabs
  • Mogene LC

Report Coverage

Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Clinical oncology next-generation sequencing Market by Category

By Component:

  • Sequencing Platforms
  • Sequencing Products
  • Kits and Reagents
  • Services

By Technology:

  • Ion Semiconductor Sequencing
  • Pyro-Sequencing
  • Synthesis Sequencing (SBS)
  • Real Time Sequencing (SMRT)
  • Ligation Sequencing
  • Reversible Dye Termination Sequencing
  • Nano-Pore Sequencing

By Application:

  • Whole Tumor Genome Sequencing
  • Whole Tumor Exome Sequencing
  • Targeted Tumor Genome Profiling
  • Tumor Transcriptome Sequencing
  • Tumor-normal Comparisons
  • Others

By End User:

  • Hospital Laboratories
  • Clinical Research Organizations
  • Diagnostic Laboratories
  • Others

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

Frequently Asked Questions

The clinical oncology next-generation sequencing market is estimated to be worth around US$ 449.4 Mn in 2022.

As per FMI, the clinical oncology next-generation sequencing market is forecast to register a CAGR of 16.3% between 2022 and 2029.

The clinical oncology next-generation sequencing market grew at a CAGR of 14.4% between 2014 and 2021.

Increasing investments by government, rising cases of cancer and surging adoption of NGS techniques in personalized medicine are some of the key trends shaping the growth of the market.

Illumina, Inc., F. Hoffmann-La Roche Ltd, Oxford Nanopore Technologies, Agilent Technologies, Thermo Fisher Scientific Inc, PerkinElmer, Inc., Becton, Dickinson and Company, QIAGEN N.V., Pacific Biosciences of California, Inc., BGI Group, Takara Bio, Inc, Creative-Biolabs and Mogene LC are some of the leading players operating in the clinical oncology next-generation sequencing market.

Table of Content

1. Executive Summary

       1.1. Global Market Outlook

       1.2. Analysis and Recommendations

2. Market Overview

       2.1. Market Coverage / Taxonomy

       2.2. Market Definition / Scope / Limitations

3. Market Background

       3.1. Macro-Economic Factors

       3.2. Forecast Factors - Relevance & Impact

       3.3. Market Dynamics

              3.3.1. Drivers

              3.3.2. Restraints

              3.3.3. Opportunities

              3.3.4. Trends

4. Key Success Factors

       4.1. Cancer Epidemiology, By Region

       4.2. Key Regulations 

5. Global Clinical Oncology Next Generation Sequencing (NGS) Market Value (US$ Mn) Analysis 2014-2021 and Forecast, 2022-2028

       5.1. Historical Market Value (US$ Mn) Analysis, 2014-2021

       5.2. Current and Future Market Value (US$ Mn) Projections, 2022-2028

              5.2.1. Y-o-Y Growth Trend Analysis

              5.2.2. Absolute $ Opportunity Analysis

6. Global Clinical Oncology Next Generation Sequencing (NGS) Market Analysis 2014-2021 and Forecast 2022-2028, by Component

       6.1. Introduction

       6.2. Historical Market Size (US$ Mn) Analysis By Component, 2014-2021

       6.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Component, 2022-2028

              6.3.1. Sequencing Platforms

              6.3.2. Sequencing Products

              6.3.3. Kits and Reagents

              6.3.4. Services

       6.4. Market Attractiveness Analysis By Component

7. Global Clinical Oncology Next Generation Sequencing (NGS) Market Analysis 2014-2021 and Forecast 2022-2028, by Technology

       7.1. Introduction

       7.2. Historical Market Size (US$ Mn) and Volume Analysis By Technology, 2014-2021

       7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Technology, 2021 - 2021

              7.3.1. Ion Semiconductor Sequencing

              7.3.2. Pyro-Sequencing

              7.3.3. Synthesis Sequencing (SBS)

              7.3.4. Real Time Sequencing (SMRT)

              7.3.5. Ligation Sequencing

              7.3.6. Reversible Dye Termination Sequencing

              7.3.7. Nano-Pore Sequencing

              7.3.8. Others

       7.4. Market Attractiveness Analysis By Application

8. Global Clinical Oncology Next Generation Sequencing (NGS) Market Analysis 2014-2021 and Forecast 2022-2028, by Application

       8.1. Introduction

       8.2. Historical Market Size (US$ Mn) By Application, 2014-2021

       8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Application, 2021 - 2021

              8.3.1. Whole Tumor Genome Sequencing

              8.3.2. Whole Tumor Exome Sequencing

              8.3.3. Targeted Tumor Genome Profiling

              8.3.4. Tumor Transcriptome Sequencing

              8.3.5. Tumor-normal Comparisons

              8.3.6. Others

       8.4. Market Attractiveness Analysis By Application

9. Global Clinical Oncology Next Generation Sequencing (NGS) Market Analysis 2014-2021 and Forecast 2022-2028, by End User

       9.1. Introduction

       9.2. Historical Market Size (US$ Mn) By End User, 2014-2021

       9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2021 - 2021

              9.3.1. Hospital Laboratories

              9.3.2. Clinical Research Organizations

              9.3.3. Diagnostic Laboratories

              9.3.4. Others

       9.4. Market Attractiveness Analysis By End User

10. Global Clinical Oncology Next Generation Sequencing (NGS) Market Analysis 2014-2021 and Forecast 2022-2028, by Region

       10.1. Introduction

       10.2. Historical Market Size (US$ Mn) Analysis By Region, 2014-2021

       10.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2021 - 2021

              10.3.1. North America

              10.3.2. Latin America

              10.3.3. Europe

              10.3.4. East Asia

              10.3.5. South Asia

              10.3.6. Oceania

              10.3.7. MEA

       10.4. Market Attractiveness Analysis By Region

11. North America Clinical Oncology Next Generation Sequencing (NGS) Market Analysis 2014-2021 and Forecast 2022-2028

       11.1. Introduction

       11.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014-2021

       11.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2028

              11.3.1. By Country

                       11.3.1.1. U.S.

                       11.3.1.2. Canada

              11.3.2. By Component

              11.3.3. By Technology

              11.3.4. By Application

              11.3.5. By End User

       11.4. Market Attractiveness Analysis

12. Latin America Clinical Oncology Next Generation Sequencing (NGS) Market Analysis 2014-2021 and Forecast 2022-2028

       12.1. Introduction

       12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014-2021

       12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2028

              12.3.1. By Country

                       12.3.1.1. Brazil

                       12.3.1.2. Mexico

                       12.3.1.3. Rest of Latin America

              12.3.2. By Component

              12.3.3. By Technology

              12.3.4. By Application

              12.3.5. By End User

       12.4. Market Attractiveness Analysis

13. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Analysis 2014-2021 and Forecast 2022-2028

       13.1. Introduction

       13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014-2021

       13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2028

              13.3.1. By Country

                       13.3.1.1. Germany

                       13.3.1.2. Italy

                       13.3.1.3. France

                       13.3.1.4. U.K.

                       13.3.1.5. Spain

                       13.3.1.6. BENELUX

                       13.3.1.7. Russia

                       13.3.1.8. Rest of Europe

              13.3.2. By Component

              13.3.3. By Technology

              13.3.4. By Application

              13.3.5. By End User

       13.4. Market Attractiveness Analysis

14. East Asia Clinical Oncology Next Generation Sequencing (NGS) Market Analysis 2014-2021 and Forecast 2022-2028

       14.1. Introduction

       14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014-2021

       14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2028

              14.3.1. By Country

                       14.3.1.1. C China

                       14.3.1.2. Japan

                       14.3.1.3. South Korea

              14.3.2. By Component

              14.3.3. By Technology

              14.3.4. By Application

              14.3.5. By End User

       14.4. Market Attractiveness Analysis

15. South Asia Clinical Oncology Next Generation Sequencing (NGS) Market Analysis 2014-2021 and Forecast 2022-2028

       15.1. Introduction

       15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014-2021

       15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2028

              15.3.1. By Country

                       15.3.1.1. India

                       15.3.1.2. Thailand

                       15.3.1.3. Indonesia

                       15.3.1.4. Malaysia

                       15.3.1.5. Rest of South Asia

              15.3.2. By Component

              15.3.3. By Technology

              15.3.4. By Application

              15.3.5. By End User

       15.4. Market Attractiveness Analysis

16. Oceania Clinical Oncology Next Generation Sequencing (NGS) Market Analysis 2014-2021 and Forecast 2022-2028

       16.1. Introduction

       16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014-2021

       16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2028

              16.3.1. By Country

                       16.3.1.1. Australia

                       16.3.1.2. New Zealand

              16.3.2. By Component

              16.3.3. By Technology

              16.3.4. By Application

              16.3.5. By End User

       16.4. Market Attractiveness Analysis

17. Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Analysis 2014-2021 and Forecast 2022-2028

       17.1. Introduction

       17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014-2021

       17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2028

              17.3.1. By Country

                       17.3.1.1. GCC Countries

                       17.3.1.2. Turkey

                       17.3.1.3. Northern Africa

                       17.3.1.4. South Africa

                       17.3.1.5. Rest of Middle East and Africa

              17.3.2. By Component

              17.3.3. By Technology

              17.3.4. By Application

              17.3.5. By End User

       17.4. Market Attractiveness Analysis

18. Emerging Countries Clinical Oncology Next Generation Sequencing (NGS) Market Analysis 2014-2021 and Forecast 2022-2028

       18.1. Introduction

              18.1.1. Market Value Proportion Analysis, By Key Countries

              18.1.2. Global Vs. Country Growth Comparison

       18.2. China Clinical Oncology Next Generation Sequencing (NGS) Market Analysis

              18.2.1. Introduction

              18.2.2. Market Value Proportion Analysis by Market Taxonomy

                       18.2.2.1. By Component

                       18.2.2.2. By Technology

                       18.2.2.3. By Application

                       18.2.2.4. By End User

       18.3. South Korea Clinical Oncology Next Generation Sequencing (NGS) Market Analysis

              18.3.1. Introduction

              18.3.2. Market Value Proportion Analysis by Market Taxonomy

                       18.3.2.1. By Component

                       18.3.2.2. By Technology

                       18.3.2.3. By Application

                       18.3.2.4. By End User

       18.4. India Clinical Oncology Next Generation Sequencing (NGS) Market Analysis

              18.4.1. Introduction

              18.4.2. Market Value Proportion Analysis by Market Taxonomy

                       18.4.2.1. By Component

                       18.4.2.2. By Technology

                       18.4.2.3. By Application

                       18.4.2.4. By End User

19. Market Structure Analysis

       19.1. Market Analysis by Tier of Companies

       19.2. Market Share Analysis of Top Players

20. Competition Analysis

       20.1. Competition Dashboard

       20.2. Competition Deep Dive

              20.2.1. Illumina, Inc.

                       20.2.1.1. Overview

                       20.2.1.2. Product Portfolio

                       20.2.1.3. Sales Footprint

                       20.2.1.4. Analysis Commentary

              20.2.2. F. Hoffmann-La Roche Ltd

              20.2.3. Oxford Nanopore Technologies

              20.2.4. Agilent Technologies

              20.2.5. Thermo Fisher Scientific Inc

              20.2.6. PerkinElmer, Inc.,

              20.2.7. Becton, Dickinson and Company

              20.2.8. QIAGEN N.V.

              20.2.9. Pacific Biosciences of California, Inc.

              20.2.10. BGI Group

              20.2.11. Takara Bio, Inc

              20.2.12. Creative-Biolabs

              20.2.13. Mogene LC

21. Assumptions and Acronyms Used

22. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 01: Global Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By Product Type

Table 02: Global Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By Technology

Table 03: Global Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By Application

Table 04: Global Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By End User

Table 05: Global Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By Region

Table 06: North America Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By Country

Table 07: North America Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By Product Type

Table 08: North America Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By Technology

Table 09: North America Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By Application

Table 10: North America Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By End User

Table 11: Latin America Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By Country

Table 12: Latin America Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By Product Type

Table 13: Latin America Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By Technology

Table 14: Latin America Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By Application

Table 15: Latin America Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By End User

Table 16: Europe Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By Country

Table 17: Europe Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By Product Type

Table 18: Europe Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By Technology

Table 19: Europe Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By Application

Table 20: Europe Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By End User

Table 21: East Asia Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By Country

Table 22: East Asia Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By Product Type

Table 23: East Asia Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By Technology

Table 24: East Asia Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By Application

Table 25: East Asia Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By End User

Table 26: South Asia Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By Country

Table 27: South Asia Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By Product Type

Table 28: South Asia Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By Technology

Table 29: South Asia Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By Application

Table 30: South Asia Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By End User

Table 31: Oceania Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By Country

Table 32: Oceania Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By Product Type

Table 33: Oceania Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By Technology

Table 34: Oceania Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By Application

Table 35: Oceania Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By End User

Table 36: MEA Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By Country

Table 37: MEA Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By Product Type

Table 38: MEA Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By Technology

Table 39: MEA Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By Application

Table 40: MEA Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By End User

Table 41: China Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By Product Type

Table 42: China Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By Technology

Table 43: China Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By Application

Table 44: China Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By End User

Table 45: South Korea Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By Product Type

Table 46: South Korea Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By Technology

Table 47: South Korea Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By Application

Table 48: South Korea Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By End User

Table 49: India Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By Product Type

Table 50: India Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By Technology

Table 51: India Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By Application

Table 52: India Clinical Oncology Next Generation Sequencing Market Value (US$) Analysis 2014-2021 and Forecast 2022-2028, By End User

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 01: Global Clinical Oncology Next Generation Sequencing Market Value Share Analysis, by Product Type (2022)

Figure 02: Global Clinical Oncology Next Generation Sequencing Market Value Share Analysis, by Technology (2022)

Figure 03: Global Clinical Oncology Next Generation Sequencing Market Value Share Analysis, by Application (2022)

Figure 04: Global Clinical Oncology Next Generation Sequencing Market Value Share Analysis, by End User (2022)

Figure 05: Global Clinical Oncology Next Generation Sequencing Market Value Share Analysis, by Region (2022)

Figure 06: Global Clinical Oncology Next Generation Sequencing Market Size and Y-o-Y, 2014–2021

Figure 07: Global Clinical Oncology Next Generation Sequencing Market Size (US$ Mn) & Y-o-Y Growth (%), 2022–2028

Figure 08: Global Clinical Oncology Next Generation Sequencing Market Absolute $ Opportunity, 2021–2028

Figure 09: Global Clinical Oncology Next Generation Sequencing Market Value Share Analysis (%) By Product Type, 2022 & 2028

Figure 10: Global Clinical Oncology Next Generation Sequencing Market Y-o-Y Growth (%) Analysis, By Product Type, 2022–2028

Figure 11: Global Clinical Oncology Next Generation Sequencing Market Attractiveness Analysis, By Product Type

Figure 12: Global Clinical Oncology Next Generation Sequencing Market Value Share Analysis (%) By Technology, 2022 & 2028

Figure 13: Global Clinical Oncology Next Generation Sequencing Market Y-o-Y Growth (%) By Technology, 2022–2028

Figure 14: Global Clinical Oncology Next Generation Sequencing Market Attractiveness Analysis, By Technology

Figure 15: Global Clinical Oncology Next Generation Sequencing Market Value Share Analysis (%) By Application, 2022 & 2028

Figure 16: Global Clinical Oncology Next Generation Sequencing Market Y-o-Y Growth (%) By Application, 2022–2028

Figure 17: Global Clinical Oncology Next Generation Sequencing Market Attractiveness Analysis, By Application

Figure 18: Global Clinical Oncology Next Generation Sequencing Market Share Analysis (%) By End User, 2022 & 2028

Figure 19: Global Clinical Oncology Next Generation Sequencing Market Y-o-Y Growth (%) By End User, 2022–2028

Figure 20: Global Clinical Oncology Next Generation Sequencing Market Attractiveness Analysis, By End User

Figure 21: Global Clinical Oncology Next Generation Sequencing Market Share Analysis (%) By Region, 2022 & 2028

Figure 22: Global Clinical Oncology Next Generation Sequencing Market Y-o-Y Growth (%) By Region, 2022–2028

Figure 23: Global Clinical Oncology Next Generation Sequencing Market Attractiveness Analysis, By Region

Figure 24: North America Clinical Oncology Next Generation Sequencing Market Value Share Analysis, by Product Type (2022)

Figure 25: North America Clinical Oncology Next Generation Sequencing Market Value Share Analysis, by Technology (2022)

Figure 26: North America Clinical Oncology Next Generation Sequencing Market Value Share Analysis, by Application (2022)

Figure 27: North America Clinical Oncology Next Generation Sequencing Market Value Share Analysis, by End User (2022)

Figure 28: North America Clinical Oncology Next Generation Sequencing Market Value Share Analysis, by Country (2022)

Figure 29: North America Clinical Oncology Next Generation Sequencing Market Size (US$ Mn) Analysis, 2014-2021

Figure 30: North America Clinical Oncology Next Generation Sequencing Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 31: North America Clinical Oncology Next Generation Sequencing Market Attractiveness Analysis, By Product Type

Figure 32: North America Clinical Oncology Next Generation Sequencing Market Attractiveness Analysis, By Technology

Figure 33: North America Clinical Oncology Next Generation Sequencing Market Attractiveness Analysis, By Application

Figure 34: North America Clinical Oncology Next Generation Sequencing Market Attractiveness Analysis, By End User

Figure 35: North America Clinical Oncology Next Generation Sequencing Market Attractiveness Analysis, By Country

Figure 36: Latin America Clinical Oncology Next Generation Sequencing Market Value Share Analysis, by Product Type (2022)

Figure 37: Latin America Clinical Oncology Next Generation Sequencing Market Value Share Analysis, by Technology (2022)

Figure 38: Latin America Clinical Oncology Next Generation Sequencing Market Value Share Analysis, by Application (2022)

Figure 39: Latin America Clinical Oncology Next Generation Sequencing Market Value Share Analysis, by End User (2022)

Figure 40: Latin America Clinical Oncology Next Generation Sequencing Market Value Share Analysis, by Country (2022)

Figure 41: Latin America Clinical Oncology Next Generation Sequencing Market Size (US$ Mn) Analysis, 2014-2021

Figure 42: Latin America Clinical Oncology Next Generation Sequencing Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 43: Latin America Clinical Oncology Next Generation Sequencing Market Attractiveness Analysis, By Product Type

Figure 44: Latin America Clinical Oncology Next Generation Sequencing Market Attractiveness Analysis, By Technology

Figure 45: Latin America Clinical Oncology Next Generation Sequencing Market Attractiveness Analysis, By Application

Figure 46: Latin America Clinical Oncology Next Generation Sequencing Market Attractiveness Analysis, By End User

Figure 47: Latin America Clinical Oncology Next Generation Sequencing Market Attractiveness Analysis, By Country

Figure 48: Europe Clinical Oncology Next Generation Sequencing Market Value Share Analysis, by Product Type (2022)

Figure 49: Europe Clinical Oncology Next Generation Sequencing Market Value Share Analysis, by Technology (2022)

Figure 50: Europe Clinical Oncology Next Generation Sequencing Market Value Share Analysis, by Application (2022)

Figure 51: Europe Clinical Oncology Next Generation Sequencing Market Value Share Analysis, by End User (2022)

Figure 52: Europe Clinical Oncology Next Generation Sequencing Market Value Share Analysis, by Country (2022)

Figure 53: Europe Clinical Oncology Next Generation Sequencing Market Size (US$ Mn) Analysis, 2014-2021

Figure 54: Europe Clinical Oncology Next Generation Sequencing Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 55: Europe Clinical Oncology Next Generation Sequencing Market Attractiveness Analysis, By Product Type

Figure 56: Europe Clinical Oncology Next Generation Sequencing Market Attractiveness Analysis, By Technology

Figure 57: Europe Clinical Oncology Next Generation Sequencing Market Attractiveness Analysis, By Application

Figure 58: Europe Clinical Oncology Next Generation Sequencing Market Attractiveness Analysis, By End User

Figure 59: Europe Clinical Oncology Next Generation Sequencing Market Attractiveness Analysis, By Country

Figure 60: East Asia Clinical Oncology Next Generation Sequencing Market Value Share Analysis, by Product Type (2022)

Figure 61: East Asia Clinical Oncology Next Generation Sequencing Market Value Share Analysis, by Technology (2022)

Figure 62: East Asia Clinical Oncology Next Generation Sequencing Market Value Share Analysis, by Application (2022)

Figure 63: East Asia Clinical Oncology Next Generation Sequencing Market Value Share Analysis, by End User (2022)

Figure 64: East Asia Clinical Oncology Next Generation Sequencing Market Value Share Analysis, by Country (2022)

Figure 65: East Asia Clinical Oncology Next Generation Sequencing Market Size (US$ Mn) Analysis, 2014-2021

Figure 66: East Asia Clinical Oncology Next Generation Sequencing Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 67: East Asia Clinical Oncology Next Generation Sequencing Market Attractiveness Analysis, By Product Type

Figure 68: East Asia Clinical Oncology Next Generation Sequencing Market Attractiveness Analysis, By Technology

Figure 69: East Asia Clinical Oncology Next Generation Sequencing Market Attractiveness Analysis, By Application

Figure 70: East Asia Clinical Oncology Next Generation Sequencing Market Attractiveness Analysis, By End User

Figure 71: East Asia Clinical Oncology Next Generation Sequencing Market Attractiveness Analysis, By Country

Figure 72: South Asia Clinical Oncology Next Generation Sequencing Market Value Share Analysis, by Product Type (2022)

Figure 73: South Asia Clinical Oncology Next Generation Sequencing Market Value Share Analysis, by Technology (2022)

Figure 74: South Asia Clinical Oncology Next Generation Sequencing Market Value Share Analysis, by Application (2022)

Figure 75: South Asia Clinical Oncology Next Generation Sequencing Market Value Share Analysis, by End User (2022)

Figure 76: South Asia Clinical Oncology Next Generation Sequencing Market Value Share Analysis, by Country (2022)

Figure 77: South Asia Clinical Oncology Next Generation Sequencing Market Size (US$ Mn) Analysis, 2014-2021

Figure 78: South Asia Clinical Oncology Next Generation Sequencing Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 79: South Asia Clinical Oncology Next Generation Sequencing Market Attractiveness Analysis, By Product Type

Figure 80: South Asia Clinical Oncology Next Generation Sequencing Market Attractiveness Analysis, By Technology

Figure 81: South Asia Clinical Oncology Next Generation Sequencing Market Attractiveness Analysis, By Application

Figure 82: South Asia Clinical Oncology Next Generation Sequencing Market Attractiveness Analysis, By End User

Figure 83: South Asia Clinical Oncology Next Generation Sequencing Market Attractiveness Analysis, By Country

Figure 84: Oceania Clinical Oncology Next Generation Sequencing Market Value Share Analysis, by Product Type (2022)

Figure 85: Oceania Clinical Oncology Next Generation Sequencing Market Value Share Analysis, by Technology (2022)

Figure 86: Oceania Clinical Oncology Next Generation Sequencing Market Value Share Analysis, by Application (2022)

Figure 87: Oceania Clinical Oncology Next Generation Sequencing Market Value Share Analysis, by End User (2022)

Figure 88: Oceania Clinical Oncology Next Generation Sequencing Market Value Share Analysis, by Country (2022)

Figure 89: Oceania Clinical Oncology Next Generation Sequencing Market Size (US$ Mn) Analysis, 2014-2021

Figure 90: Oceania Clinical Oncology Next Generation Sequencing Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 91: Oceania Clinical Oncology Next Generation Sequencing Market Attractiveness Analysis, By Product Type

Figure 92: Oceania Clinical Oncology Next Generation Sequencing Market Attractiveness Analysis, By Technology

Figure 93: Oceania Clinical Oncology Next Generation Sequencing Market Attractiveness Analysis, By Application

Figure 94: Oceania Clinical Oncology Next Generation Sequencing Market Attractiveness Analysis, By End User

Figure 95: Oceania Clinical Oncology Next Generation Sequencing Market Attractiveness Analysis, By Country

Figure 96: MEA Clinical Oncology Next Generation Sequencing Market Value Share Analysis, by Product Type (2022)

Figure 97: MEA Clinical Oncology Next Generation Sequencing Market Value Share Analysis, by Technology (2022)

Figure 98: MEA Clinical Oncology Next Generation Sequencing Market Value Share Analysis, by Application (2022)

Figure 99: MEA Clinical Oncology Next Generation Sequencing Market Value Share Analysis, by End User (2022)

Figure 100: MEA Clinical Oncology Next Generation Sequencing Market Value Share Analysis, by Country (2022)

Figure 101: MEA Clinical Oncology Next Generation Sequencing Market Size (US$ Mn) Analysis, 2014-2021

Figure 102: MEA Clinical Oncology Next Generation Sequencing Market Size (US$ Mn) Forecast & Y-o-Y Growth (%), 2022-2028

Figure 103: MEA Clinical Oncology Next Generation Sequencing Market Attractiveness Analysis, By Product Type

Figure 104: MEA Clinical Oncology Next Generation Sequencing Market Attractiveness Analysis, By Technology

Figure 105: MEA Clinical Oncology Next Generation Sequencing Market Attractiveness Analysis, By Application

Figure 106: MEA Clinical Oncology Next Generation Sequencing Market Attractiveness Analysis, By End User

Figure 107: MEA Clinical Oncology Next Generation Sequencing Market Attractiveness Analysis, By Country

Figure 108: Global Oncology Next Generation Sequencing Market Value Proportion Analysis, By Emerging Countries, 2022

Figure 109: Oncology Next Generation Sequencing Market, Global Vs. Country Growth Y-o-Y (%) Comparison, 2021-2028

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Metagenomics Market

Published : February 2022

Healthcare

Paediatric Oncology Therapeutics Market

Published : January 2017

Healthcare

Musculoskeletal Oncology Therapeutics Market

Published : June 2016

Healthcare

Orthopedic Oncology Market

Published : May 2016

Google translate

Clinical Oncology Next-generation Sequencing Market